CAMBRIDGE, Mass.–(BUSINESS WIRE)–Walden Biosciences, Inc. (Walden), a biotechnology company focused on transforming the treatment of kidney disease, today announced its launch with a $51 million Series A financing led by ARCH Venture Partners and UCB Ventures. Walden is seeking to develop breakthrough medicines that reverse the progression of both rare and common forms of kidney disease and restore renal function. The majority of renal drug development approaches focus on reducing general phy
Welcome! Log into your account
Recover your password
A password will be e-mailed to you.